Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.46 |
| ▸ | KIF11 | P52732 | 6/20 | 0.36 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | PKLR | P30613 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6754126 | 1.00 | AR (0.46) | ARKIF11SRD5A1MTNR1APKM | |
| SCHEMBL6754125 | 1.00 | AR (0.46) | ARKIF11SRD5A1MTNR1APKM | |
| SCHEMBL27654170 | 0.90 | AR (0.52) | ARKIF11SRD5A1MTNR1AHTR2A | |
| SCHEMBL30738393 | 0.90 | AR (0.52) | ARKIF11SRD5A1MTNR1AHTR2A | |
| Ethoxycarbonyl Group SCHEMBL29291835 | 0.81 | AR (0.46) | ARKIF11SRD5A1MTNR1ACYP26A1 | |
| SCHEMBL9064740 | 0.80 | AR (0.50) | ARMTNR1AHTR2AHTR2CHTR2B | |
| SCHEMBL6754202 | 0.79 | AR (0.38) | ARKIF11SRD5A1 | |
| SCHEMBL6754201 | 0.79 | AR (0.38) | ARKIF11SRD5A1 | |
| SCHEMBL6752929 | 0.79 | AR (0.40) | ARKIF11SRD5A1MTNR1AHTR2A | |
| SCHEMBL6752928 | 0.79 | AR (0.40) | ARKIF11SRD5A1MTNR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6713468-B2 | AS ANTICONVULSANTS; FOR THERAPY AND PROPHYLAXIS OF ISCHAEMIAS, ANOXIA, NEURODEGENERATIVE DISEASES | AVENTIS PHARMA S.A. (FR) | 2004-03-30 | — | — | US | disclosed |
| US-20030055031-A1 | Methods of using thiazolobenzoheterocycles | RHONE-POULENC RORER S.A. | 2003-03-20 | — | — | US | disclosed |
| US-6448241-B1 | THESE COMPOUNDS ARE ANTICONVULSANTS AND INTERFERE WITH GLUTAMATERGIC TRANSMISSION AND ARE THEREFORE USEFUL FOR THE TREATMENT OR PREVENTION OF ALL ISCHAEMIAS FOLLOWING CEREBROVASCULAR ACCIDENTS | AVENTIS PHARMA S.A. (FR) | 2002-09-10 | — | — | US | disclosed |
| US-6423715-B1 | ANTICONVULSANTS | AVENTIS PHARMA S.A. (FR) | 2002-07-23 | — | — | US | disclosed |
| US-6288075-B1 | ANTIEPILEPTIC AGENTS; NERVOUS SYSTEM, BRAIN, AND CARDIOVASCULAR DISORDERS | RHONE-POULENC RORER S.A. (FR) | 2001-09-11 | — | — | US | disclosed |
| EP-0966473-A1 | THIAZOLOBENZOHETEROCYCLES, PREPARATION AND MEDICINES CONTAINING SAME | Aventis Pharma S.A. (FR) | 1999-12-29 | — | — | EP | disclosed |
| WO-1998038194-A1 | THIAZOLOBENZOHETEROCYCLES, PREPARATION AND MEDICINES CONTAINING SAME | RHONE-POULENC RORER S.A. (FR) | 1998-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055031-A1 | Methods of using thiazolobenzoheterocycles | SLCO2B1, SLCO1B1, CYP21A2 | AR 1167/4885KIF11 4115/4885SRD5A1 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.